EPCAM/CD326 (Oportuzumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-EPCAM/CD326 (Oportuzumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | EPCAM/CD326 (Oportuzumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Oportuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EPCAM/CD326, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A. |
| Immunogen | n/a |
| Other Names | Oportuzumab, EPCAM/CD326, 945228-48-8 |
| Gene, Accession # | CAS: 945228-48-8 |
| Catalog # | abx831126 |
| Price | please inquire |
| Order / More Info | EPCAM/CD326 (Oportuzumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies